Novartis $3.2B deal

This $3.2 Billion Novartis Bet Is Not a New Drug. It Is a Better Way to Take One

Novartis committed $3.2 billion to license Alteogen's Hybrozyme platform, enabling subcutaneous delivery of existing biologics to combat biosimilar competition. The enzyme technology improves absorpti